Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference
September 19 2023 - 5:30AM
Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical
company developing a new class of complement-based medicines for
patients with classical complement-mediated autoimmune,
neurodegenerative and ophthalmic disorders, today announced that
Douglas Love, president and chief executive officer, will
participate in a fireside chat during the 2023 Cantor Global
Healthcare Conference on Tuesday, September 26, 2023 at 8:10 a.m.
ET in NYC.
A live webcast of the event can be accessed under the ‘Events
& Presentations’ section on the Investors page at
www.annexonbio.com. A replay of the webcast will be archived on the
Annexon website for 30 days following the presentation.
About Annexon
Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical
company seeking to bring game-changing medicines to patients with
classical complement-mediated diseases of the body, brain and eye.
The classical complement pathway within the immune system, when
overactivated, drives inflammation in a host of autoimmune,
neurodegenerative and ophthalmic diseases. Annexon is advancing a
new class of complement medicines targeting the early classical
cascade and all downstream pathway components that contribute to
disease, while selectively preserving the beneficial immune
functions of the other complement pathways. Annexon is rigorously
developing a pipeline of diversified product candidates across
multiple mid- to late-stage clinical trials, with clinical data
anticipated throughout 2023 and beyond.
Investor Contact:Chelcie ListerTHRUST Strategic
Communicationschelcie@thrustsc.com
Media Contact:Sheryl SeapyReal
Chemistry949-903-4750sseapy@realchemistry.com
Annexon (NASDAQ:ANNX)
Historical Stock Chart
From Apr 2024 to May 2024
Annexon (NASDAQ:ANNX)
Historical Stock Chart
From May 2023 to May 2024